As Aerie Pharmaceuticals INC (AERI) Share Price Declined, Holder Partner Fund Management LP Raised Holding

March 14, 2018 - By Stephen Andrade

Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.56, from 1.17 in 2017Q2. It is positive, as 14 investors sold AERI shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported. Parametric Port Associates Lc holds 0% or 91,222 shares. Iguana Health Ltd Liability Company holds 100,000 shares or 2.71% of its portfolio. Granite Point Management Limited Partnership holds 49,800 shares or 0.51% of its portfolio. Hanseatic reported 0% stake. Manufacturers Life Ins The has invested 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Raymond James holds 0.01% or 58,633 shares. American Century Companies Inc has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Retail Bank Of Mellon Corp has invested 0.01% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Perigon Wealth Mgmt Ltd Co, California-based fund reported 1,098 shares. The Minnesota-based Ameriprise has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Vanguard stated it has 3.00M shares or 0.01% of all its holdings. Financial Bank Of Nova Scotia has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Kazazian Asset Management Limited Com reported 14,577 shares or 0.87% of all its holdings. Driehaus Capital Ltd Limited Liability Company stated it has 97,518 shares. Paloma Prtn Company holds 0% or 5,573 shares in its portfolio.

Christopher Medlock James increased its stake in Aerie Pharmaceuticals Inc (AERI) by 38.07% based on its latest 2017Q3 regulatory filing with the SEC. Partner Fund Management Lp bought 665,421 shares as the company’s stock declined 8.47% while stock markets rallied. The hedge fund run by Christopher Medlock James held 2.41M shares of the health care company at the end of 2017Q3, valued at $117.29M, up from 1.75 million at the end of the previous reported quarter. Partner Fund Management Lp who had been investing in Aerie Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.29 billion market cap company. The stock decreased 0.09% or $0.05 during the last trading session, reaching $57.9. About 236,630 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since March 14, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Partner Fund Management Lp, which manages about $5.09 billion US Long portfolio, decreased its stake in Visa Inc (NYSE:V) by 371,543 shares to 190,147 shares, valued at $20.01M in 2017Q3, according to the filing. It also reduced its holding in Clovis Oncology Inc (Prn) by 12.08M shares in the quarter, leaving it with 34.71M shares, and cut its stake in Humana Inc (NYSE:HUM).

More notable recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: which released: “Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel” on February 20, 2018, also with their article: “Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial …” published on February 28, 2018, published: “Why Earnings Season Could Be Great for Aerie Pharmaceuticals (AERI) February …” on February 27, 2018. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were released by: and their article: “Aerie Pharmaceuticals to Present at the Cowen and Company 38” published on February 21, 2018 as well as‘s news article titled: “Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28” with publication date: February 28, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 49 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 17 by Stifel Nicolaus. The company was maintained on Tuesday, January 2 by Stifel Nicolaus. The company was maintained on Friday, September 22 by JMP Securities. The firm has “Buy” rating by Cowen & Co given on Tuesday, September 26. Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Friday, August 7. Cantor Fitzgerald has “Buy” rating and $30 target. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cowen & Co on Thursday, November 9. The rating was initiated by Mizuho on Wednesday, September 6 with “Buy”. As per Wednesday, September 14, the company rating was initiated by Raymond James. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Tuesday, November 1 by Aegis Capital. The firm has “Buy” rating given on Wednesday, October 11 by Cantor Fitzgerald.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: